Clinical Trial Update: Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial [Phase 2]

View source ↗

Summary

A Phase 2 trial (FIXER) is evaluating intravitreal methotrexate to prevent proliferative vitreoretinopathy during primary retinal detachment repair and is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Vitreoretinopathy
• Rhegmatogenous Retinal Detachment

Drugs mentioned

• Methotrexate (intravitreal) (Methotrexate)

Snippet

Sponsor: Cincinnati Eye Institute, Southwest Ohio | Conditions: Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment | Phase 2 | Status: RECRUITING